Canaccord Genuity Initiates Coverage On Seaport Therapeutics with Buy Rating, Announces Price Target of $28

Benzinga · 3d ago
Canaccord Genuity analyst Sumant Kulkarni initiates coverage on Seaport Therapeutics (NASDAQ:SPTX) with a Buy rating and announces Price Target of $28.